Inhibition of HIV-1 infectivity with curdlan sulfate in vitro.
Kaneko
Y
Y
Ajinomoto Co., Inc., Tokyo, Japan.
Yoshida
O
O
Nakagawa
R
R
Yoshida
T
T
Date
M
M
Ogihara
S
S
Shioya
S
S
Matsuzawa
Y
Y
Nagashima
N
N
Irie
Y
Y
D000818:Animals; D000998:Antiviral Agents; D015496:CD4-Positive T-Lymphocytes / Q000382:microbiology; D002460:Cell Line; D005936:Glucans / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D006168:Guinea Pigs; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007928:Lethal Dose 50; D051379:Mice; D051381:Rats; D011919:Rats, Inbred Strains; D047071:beta-Glucans
D000998:Antiviral Agents; D005936:Glucans; D047071:beta-Glucans; C063130:curdlan sulfate